M ajor depressive disorder (MDD) is a serious mental illness with a 1-year prevalence rate of 4.1% to 4.8% in Canada and a lifetime prevalence of 8%. 1 The human cost of the illness in terms of impaired social and emotional functioning cannot be emphasized enough, and the societal burden from an economic standpoint alone is substantial. According to the WHO, the disability levels caused by depression are even higher than those caused by other common medical conditions, including arthritis, hypertension, and diabetes. 2 Emerging evidence also suggests an overlapping pathoetiology between mood disorders and other chronic medical conditions such as diabetes mellitus and cardiovascular disease. As such, few would argue with the need for effective treatments for depression. Although comparable outcomes have been reported for pharmacotherapy and evidence-based psychotherapies, antidepressant medications are the most available first-line treatments for moderate-to-severe major depressive episodes.
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"Effectiveness" and the Scope of the Debate
For the purpose of this debate, current first-line selective serotonin reuptake inhibitors and dual-action agents will be considered to represent antidepressants and the term "effective" will reflect real-world outcome when these medications are prescribed under some form of measurement-based conditions. This is explicitly not a debate about efficacy and the difference between active treatment and placebo outcomes. It is implicitly about the evidence to support a disease-centred model of depression and the capacity to demonstrate that antidepressants alter the depressive substrate.
According to Moncrieff and Cohen, 3 the challenge in supporting a disease-centred model for MDD is to present evidence that drugs correct an abnormal brain state, that therapeutic results are related to a favourable impact on disease pathology, and that effects differ between patients and volunteers.
These criteria are borrowed from other systemic disorders such as diabetes mellitus, where this model of disease and the therapeutic effects of treatments can be readily evaluated. Until recently, limited technology and understanding of brain complexity have delayed the application of these criteria to depression.
Evidence to Support the Disease-Centred Model of Depression
There is ample evidence at varying levels of analysis to make this case. At the neuropsychological level, altered cognition, executive function, and reward behaviour, as well as neurobiological findings including alterations to circadian rhythm, the hypothalamo-pituitary-adrenal axis, or the immune system, are frequently demonstrated in states of clinical depression. Studies of stress and depression have more recently focused on the effects of stress on neurotrophic factors implicated in mood disorders. Brain-derived neurotrophic factor (BDNF) is one protein, important in neuronal development and survival, that has been of particular interest insofar as both acute and chronic stress tend to decrease its expression. However, increasing data suggest that antidepressants upregulate the production of BDNF, enhancing hippocampal neurogenesis and promoting neuroplasticity. 4 Still, the most germane evidence in support of the disease-centred model of depression and antidepressant effectiveness is derived from structural and functional neuroimaging studies. Structural imaging studies have demonstrated that recurrent episodes of depression and a longer duration of untreated illness correlate with decreased hippocampal volume and with neurocognitive impairment 5 ; in contrast, the same relation did not appear in patients treated with antidepressants. Further, depression patients treated with antidepressants have shown improved performance on various neurocognitive measures, compared with untreated depression patients. 6 At the level of functional neuroimaging, glucose metabolism studies are instructive in regard to all 3 requirements for the disease-centred model. The induction of sadness in healthy volunteers has been shown to increase metabolic activity in cingulate area 25 (a baseline difference from patient populations), 7 whereas the response to treatment with paroxetine resulted in a reduction of hypermetabolism in cingulate area 25. 8 These findings have been replicated with other physical and psychological treatments and are distinct from the effects of placebo on regional brain activity, 9 making the point that regional brain abnormalities are present in depression, are reversed in antidepressant responders, and are not replicated by placebo. Using challenge paradigms, others have demonstrated abnormal responses in depression patients before treatment, compared with control subjects, and that these abnormalities are significantly reduced with effective treatment.
Effectiveness Studies and Functional Outcomes
Arguments that antidepressants are not effective do a disservice to the quest for better multidimensional diagnostic methods to define subgroups within the heterogeneous MDD construct and, hence, to improve the fit between therapeutic agents and their targets. If there is a lesson to be learned from the Sequenced Treatment Alternatives to Relieve Depression sequence of trials, which applied measurement-based care to depression patients in both primary care and psychiatric practice settings, it is that effective treatments are available when a systematic approach to switching, combining, and augmenting agents is followed. 10 Although less than 30% of study patients achieved remission after a single trial of citalopram, sequential trials resulted in more than 50% of the originally enrolled patients meeting the most rigorous outcome standard: remission. The future challenge is to customize antidepressant therapy.
The functional outcome of antidepressant treatment is also important in addressing effectiveness. In the workplace, depression has an enormous impact on absenteeism, presenteeism, and "the bottom line." We offer 2 brief examples: First, employees who returned to work were significantly more likely to have been prescribed first-line antidepressant agents at adequate dosages, compared with those who claimed long-term disability payments. 11 Second, optimal use of antidepressants has been shown to reduce absenteeism and enhance productivity. 12 Maintenance antidepressant treatment is also associated with significantly better quality-of-life outcomes, compared with placebo. 13 At endpoint, not only was there a significant worsening in psychosocial functioning in those patients taking placebo, the patients who relapsed experienced a loss of psychosocial gains made in the acute phase.
In summary, MDD is a highly prevalent illness, with evidence to support its biological basis coming from multiple sources, including neurochemical and neuroimaging studies. Because of the range of physical, social, and societal sequelae that can result, detection, diagnosis, and effective treatment are of paramount importance. Given the robust findings that treatment to remission in depression ultimately improves function and reduces relapse and recurrence, remission has become the desired endpoint for antidepressant treatment today. There is also increasing evidence that antidepressants improve quality of life, are cost-effective, and help to reduce the financial burden imposed on society by depression. Although other approaches to depression, including lifestyle changes, psychoeducation, and structured psychotherapies, play an important role, pharmacotherapy remains a cornerstone of effective treatment of depression.
